Publications by authors named "B J Landi"
Article Synopsis
- A study called IMADGIST assessed whether extending adjuvant imatinib treatment for an additional three years (totaling six years) improved disease-free survival in patients with high-risk localized gastrointestinal stromal tumors (GIST) who had already received three years of treatment after surgery.
- Conducted across 14 centers, the trial included 136 patients with varied risks of tumor recurrence, finding that those treated for six years had significantly better disease-free survival compared to those who stopped after three years.
- Although there was no significant difference in overall survival, time to imatinib resistance, or quality of life between the two groups, the results suggest that extending treatment can effectively lower relapse rates with
Objective: The anticancer properties of recombinant α-luffin (LUF) are wellestablished. However, the cytotoxic effects of encapsulating LUF within niosomes on the SKBR3 breast cancer cell line have yet to be explored. Our study aimed to investigate whether this encapsulation strategy could improve cytotoxic effects.
View Article and Find Full Text PDFArticle Synopsis
- In a phase III study of metastatic colorectal cancer, two treatment sequences were compared: FOLFIRI followed by FOLFOX6 (arm A) versus FOLFOX6 followed by FOLFIRI (arm B).
- Both treatment sequences resulted in similar median survival times (21.5 months for arm A and 20.6 months for arm B) and comparable response rates in first-line therapy (56% for FOLFIRI vs. 54% for FOLFOX6).
- However, the treatments had different toxicity profiles, with FOLFIRI showing higher rates of mucositis and nausea/vomiting, while FOLFOX6 had more cases of neutropenia and sensory toxicity.
Gastrointestinal tumors in transplantation: Two case reports and review of literature.
World J Gastroenterol
September 2022
Background: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. As most of them harbor a mutation (75%), selective kinase inhibitors are the therapeutic option and show a sustained objective response among patients with metastatic or unresectable GISTs. A well-known higher risk of neoplasm has been described among renal transplant recipients (RTRs).
View Article and Find Full Text PDFThe deep sea survivability and biofouling characteristics of corrosion-resistant bulk carbon nanotubes (CNTs) have been studied after deployment in the Atlantic Ocean over the course of 12 months. Quantification of barnacle count, biofouling density, and non-combustible residue shows cyanoacrylate coatings increase durability and reduce the colonization of biofouling compared to as-received CNTs. Scanning electron microscopy was performed on the biofouled CNTs, and the majority of species were identified as diatoms, consisting of an ordered silica cell wall.
View Article and Find Full Text PDF